IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Teva Pharmaceutical to Acquire Barr for $7.46 Billion

11:02 AM MDT | July 29, 2008 | Deepti Ramesh

Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) says it has signed a definitive agreement to acquire specialty pharma firm Barr Pharmaceuticals (Montvale, NJ), the fourth-largest generic drug company worldwide, for about $7.46 billion. Teva will also assume Barr’s outstanding net debt of about $1.5 billion. The transaction is expected to close by year-end. Barr develops and manufactures generic and proprietary drugs, active pharma ingredients (APIs), and biopharmaceuticals. Yanai: Strengthen leadership in the U.S. The deal “will enhance our...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa